AstraZeneca Archives - Pharmaphorum

AZ to continue with investment freeze following ‘no deal’ Brexit

AstraZeneca will keep manufacturing investments in Britain on hold if the UK’s negotiations with Brussels fail to provide

AZ to continue with investment freeze following ‘no deal’ Brexit

https://pharmaphorum.com/news/az-to-continue-with-investment-freeze-following-no-deal-brexit/

Novo Nordisk poaches AZ’s Helfgott to run Biopharm business

Novo Nordisk has poached a top executive from AstraZeneca, tasking Ludovic Helfgott to lead development of its haemophilia

Novo Nordisk poaches AZ’s Helfgott to run Biopharm business

https://pharmaphorum.com/news/novo-nordisk-poaches-azs-helfgott-to-run-biopharm-business/

AZ’s old R&D site at heart of multimillion pound science property venture

AstraZeneca’s new R&D headquarters in Cambridge may be having teething problems – but ironically the site at Alderley

AZ’s old R&D site at heart of multimillion pound science property venture

https://pharmaphorum.com/news/alderley-park-at-heart-of-multimillion-pound-science-property-venture/

Lilly unveils promising data from dual-action diabetes drug

Eli Lilly’s investigational diabetes drug has shown early promise as a possible aid to overcoming obesity in trial

Lilly unveils promising data from dual-action diabetes drug

https://pharmaphorum.com/news/lilly-diabetes-unveils-promising-data-from-dual-action-diabetes-drug/

FDA says Clovis’ Rubraca could be prostate cancer breakthrough

Clovis Oncology’s Rubraca (rucaparib) has been designated as a Breakthrough Therapy by the FDA in prostate cancer, paving

FDA says Clovis’ Rubraca could be prostate cancer breakthrough

https://pharmaphorum.com/news/fda-says-clovis-rubraca-could-be-prostate-cancer-breakthrough/

Novo to market ‘connected’ insulin pens next year

Novo Nordisk is to launch “connected” insulin pens, responding for demands from patients for devices able to communicate

Novo to market ‘connected’ insulin pens next year

https://pharmaphorum.com/news/novo-to-market-connected-insulin-pens-next-year/

AZ grabs EU approval for Imfinzi in advanced lung cancer

The European Commission has approved AstraZeneca’s immunotherapy drug Imfinzi (durvalumab) in a kind of lung cancer that was

AZ grabs EU approval for Imfinzi in advanced lung cancer

https://pharmaphorum.com/news/az-grabs-eu-approval-for-imfinzi-in-advanced-lung-cancer/

Study shows AZ’s Farxiga diabetes drug cuts heart risks

AstraZeneca’s Farxiga has become the latest type 2 diabetes drug to show it can reduce cardiovascular risk in

Study shows AZ’s Farxiga diabetes drug cuts heart risks

https://pharmaphorum.com/news/study-shows-azs-farxiga-diabetes-drug-cuts-heart-risks/

Digital news round-up: AZ taps into China with robots, and ECG app wars

Richard Staines presents his weekly round-up of the latest digital health stories

Digital news round-up: AZ taps into China with robots, and ECG app wars

https://pharmaphorum.com/views-analysis-digital/astrazeneca-taps-into-china-with-robots-and-ecg-app-wars/

Trending

AstraZeneca

Hello World

AZ to continue with investment freeze following ‘no deal’ Brexit

Novo Nordisk poaches AZ’s Helfgott to run Biopharm business

AZ’s old R&D site at heart of multimillion pound science property venture

Lilly unveils promising data from dual-action diabetes drug

FDA says Clovis’ Rubraca could be prostate cancer breakthrough

Novo to market ‘connected’ insulin pens next year

AZ grabs EU approval for Imfinzi in advanced lung cancer

Study shows AZ’s Farxiga diabetes drug cuts heart risks

Digital news round-up: AZ taps into China with robots, and ECG app wars

Search

Advanced Search

Trending

AstraZeneca

Hello World